Go Pro
NASDAQ:QUCY

Mainz Biomed Q4 2025 Earnings Report

$1.08 -0.03 (-2.70%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.10 +0.02 (+1.48%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mainz Biomed EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mainz Biomed Revenue Results

Actual Revenue
$0.13 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mainz Biomed Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Mainz Biomed Earnings Headlines

Mainz Biomed NV (NASDAQ:QUCY) Short Interest Up 75.8% in June
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
See More Mainz Biomed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mainz Biomed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mainz Biomed and other key companies, straight to your email.

About Mainz Biomed

Mainz Biomed (NASDAQ:QUCY) B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

View Mainz Biomed Profile